REVIEW

FSH-metabolic circuitry and menopause

Charit Taneja, Sakshi Gera, Se-Min Kim, Jameel Iqbal, Tony Yuen and Mone Zaidi
The Mount Sinai Bone Program, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Correspondence should be addressed to C Taneja: charit.taneja@mountsinai.org

Abstract

FSH has a primary function in procreation, wherein it induces estrogen production in females and regulates spermatogenesis in males. However, in line with our discoveries over the past decade of non-unitary functions of pituitary hormones, we and others have described hitherto uncharacterized functions of FSH. Through high-affinity receptors, some of which are variants of the ovarian FSH receptor (FSHR), FSH regulates bone mass, adipose tissue function, energy metabolism, and cholesterol production in both sexes. These newly described actions of FSH may indeed be relevant to the pathogenesis of bone loss, dysregulated energy homeostasis, and disordered lipid metabolism that accompany the menopause in females and aging in both genders. We are therefore excited about the possibility of modulating circulating FSH levels toward a therapeutic benefit for a host of age-associated diseases, including osteoporosis, obesity and dyslipidemia, among other future possibilities.

Introduction

The early menopausal transition is associated with a sharp rise in serum FSH levels, even when serum estrogen levels remain within normal limits (Randolph et al. 2003). The median age of menopause in the United States is 51.4 years, while the average age for the start of the perimenopausal transition is 47 years, as defined by The Stages of Reproductive Aging Workshop (STRAW) (Harlow et al. 2012). This transition is marked by changes in bone remodeling, body composition, and energy metabolism, all of which are most prominent during the late perimenopause (Perrone et al. 1995, Ebeling et al. 1996, Ito et al. 1999, Chapurlat et al. 2000, Recker et al. 2000, Seifert-Klauss et al. 2002, 2006). The Study of Women’s Health Across the Nation (SWAN) studied a large cohort of perimenopausal women (42–52 years of age) and examined biological parameters, including bone mass and body fat, among others, in relation to endogenous hormone levels at various stages of the perimenopause and post-menopause (Sowers et al. 2003, 2006). The study, performed longitudinally for over a decade, revealed a decline in bone mineral density (BMD), together with increased body weight, visceral adiposity, disrupted energy homeostasis and reduced physical activity (Thurston et al. 2009, Senapati et al. 2014). The occurrence of these metabolic aberrations in the face of rising serum FSH levels with relatively unchanged serum estrogen prompted our consideration of alternate mechanism(s) of menopausal bone loss and obesity rather than the generally accepted unitary attribution to estrogen deficiency.

We published the first evidence for a role of FSH in the regulation of bone mass in mice (Sun et al. 2006). FSH increased bone resorption by enhancing the genesis and function of osteoclasts and increasing survival (Sun et al. 2006, 2010). More recent studies have shown that FSH is a primary regulator of body fat and energy homeostasis (Liu et al. 2015, 2017). Notably, we found increases in bone mass and lowered body fat in mice treated with an anti-FSH antibody, as well as in mice genetically deficient in
FSH or the FSHR (Sun et al. 2006, Liu et al. 2017, Rosen & Zaidi 2017, Ji et al. 2018). A further interesting observation was the induction of thermogenic ‘beige’ adipose tissue and, as a consequence, increased energy expenditure in antibody-treated mice (Liu et al. 2017). Extending our premise for the existence of novel pituitary-metabolic circuits of physiological and medical significance (Zaidi 2007, Zaidi et al. 2018a,b), the link between serum FSH, osteoporosis and obesity lays a firm foundation for using a single FSH-blocking agent to prevent and/or treat both postmenopausal osteoporosis and obesity.

Clinical association between FSH and bone loss

The SWAN study reported that the rate of bone loss is highest during the perimenopause period despite normal estrogen levels. The mean annual decrement in lumbar spine BMD was highest between 1 year prior to and 2 years after the last menstrual period, although the BMD values remained within normal range at this time (Sowers et al. 2003, 2006, Crandall et al. 2013). This bone loss during the menopausal transition has been confirmed by increased bone turnover markers, including N-terminal telopeptide (NTX) (Seifert-Klauss et al. 2002). A bone biopsy cohort showed evidence of increased osteoclastic resorption, noted as accelerated activation frequency as early as one year after menopause (Recker et al. 2004). Bone loss was found mainly to occur in trabecular bone, characterized histologically by decreases in trabecular number and increased trabecular perforations. Marked changes in trabecular bone structure, noted on micro-CT (µ-CT) and histomorphometry, included decreased bone volume density and trabecular number, and increased trabecular spacing (Akhter et al. 2007).

A number of correlational studies have also confirmed a relationship between rising serum FSH levels and bone loss, independently of serum estrogen (Adami et al. 2008, Xu et al. 2009, Gallagher et al. 2010, Wu et al. 2010, Garcia-Martin et al. 2012, Crandall et al. 2013). Notably, the Italian Bone Turnover Range of Normality (BONTURNO) study and a study from Spain both showed a positive correlation between high serum FSH and bone turnover markers, including osteocalcin and C-terminal telopeptide of type 1 collagen (CTX), irrespective of estradiol levels (Adami et al. 2008, Garcia-Martin et al. 2012). Likewise, a study investigating the relationship between urinary cadmium, serum FSH and femoral BMD in a cohort of women from US NHANES III (aged 42–60 years) showed an independent inverse association between FSH and BMD in certain groups (Gallagher et al. 2010). Similarly, Cannon and coworkers reported an inverse relation between FSH and BMD, independent of variables, such as serum estradiol, LH and inhibin B in 36 women between the ages of 20 and 50 years (Cannon et al. 2010). Multiple studies from China have also reported strong correlations between high serum FSH and bone loss, using bone turnover markers, BMD, and ex vivo bone resorption genes as surrogates (Xu et al. 2009, Wu et al. 2010, Cheung et al. 2011, Wang et al. 2015).

Studies investigating the patterns of bone loss in amenorrheic women have allowed a further delineation of the role of FSH on bone turnover independent of estrogen. Although women with either hypogonadotropic amenorrhea or hypergonadotropic amenorrhea were noted to have lower lumbar spine BMD compared with eumenorrheic controls, the hypergonadotropic group (FSH >40Iu/L) had significantly lower BMD compared with the hypogonadotropic amenorrheics (Devleta et al. 2004). In contrast, in a conflicting study FSH was found not to be an independent variable affecting such BMD differences in adolescent girls with hypergonadotropic or hypogonadotropic hypogonadism (Ozbek et al. 2016). These conflicting results could at least in part be explained by the difference in the mean age of females in the two studies (around 32 years vs 14 years), and may relate to the difference in the duration of excess FSH exposure between the two groups.

Molecular studies on FSH and bone loss

Starting with our discovery of the pro-resorptive action of FSH, there is now a body of incontrovertible evidence for a direct effect of FSH on bone both in vitro and in vivo (Sun et al. 2006, Liu et al. 2010a,b, Wang et al. 2015). Of note, ovariectomy-induced bone loss in rats was accentuated by the injection of FSH (Liu et al. 2010a). Furthermore, the same group reported a protective effect on bones of the injection of an FSH inhibitor (Liu et al. 2010b). As noted earlier, we have blocked FSH action using an epitope-specific anti-FSH antibody to find a rescue of post-ovariectomy bone loss (Zhu et al. 2012a, b, Ji et al. 2018).

This action of FSH on bone appears to be mediated primarily by a distinct isoform of the FSHR, which is shorter than the full-length ovarian FSHR. The presence of the FSHR isoform on human CD14+ cells and osteoclasts has been confirmed using nested PCR primers specific to the shorter isoform (Robinson et al. 2010, Tourkova et al. 2015). There is also compelling data using near-infrared spectroscopy for the binding of fluorophore-labeled...
FSH (FSH-CH) to bone in vivo, in addition to ovarian and testicular tissues (Feng et al. 2017, Ji et al. 2018). Importantly, co-injection of a 100-fold molar excess of unlabeled FSH markedly attenuated these signals, demonstrating specificity (Feng et al. 2017, Ji et al. 2018).

Unlike their coupling to Go, in ovarian follicular cells, FSHRs in bone are coupled to Goα, resulting in reduced cyclic AMP levels. This action is also associated with the sensitization of MAP kinase, NFκB and AKT pathways to stimulate osteoclastogenesis (Sun et al. 2006). In addition, FSH increases osteoclast formation by enhancing the expression of RANK, along with an increased production of cytokines, including interleukin-1β, tumor necrosis factor-α and interleukin-6 (Iqbal et al. 2006, Cannon et al. 2010, 2011).

Genetic studies investigating SNPs in the Fshr gene have further substantiated a link between FSH and bone loss. Specifically, an activating rs6166 SNP in the Fshr gene results in an increased risk of osteoporosis as seen by lower BMD and increased bone turnover markers in this group of women (Rendina et al. 2010). Moreover, digenic combinations resulting in skeletal protection were noted to have involvement of the BMP15 and Fshr genes (Mendoza et al. 2012).

**Development of highly specific blocking antibodies to FSH**

The biggest challenge with studying FSH action on bone in vivo is the confounding effects of estrogen, which change simultaneously with altered FSH signaling. While FSH can cause bone loss, it also promotes the secretion of ovarian estrogen – its primary biological function – and this results in protection of the otherwise pro-resorptive action of FSH.

Our anti-FSH antibody was generated with the goal of inhibiting FSH with minimal effects on estrogen. For this, we selected a 13-amino-acid-long peptide sequence on FSHβ, which, we knew from computational modeling, would prevent the access of FSH into the FSHR pocket (Zhu et al. 2012a,b, Ji et al. 2018). Thus, we were able to titrate circulating levels of the antibody to inhibit FSH action on osteoclasts, while sparing ovarian function (Zhu et al. 2012a). This level of specificity would not have, at least in principle, been obtainable with an anti-FSHR antibody. When the polyclonal antibody was injected into ovariectomized mice, there was not only a reduction in osteoclastic bone resorption, but also an increase in new bone formation, prompting the exploration of osteoblastic FSHRs (Zhu et al. 2012a). Notably, we discovered that FSHRs were present on osteoblast precursors, rather than on mature bone-forming osteoblasts. We have now raised and tested the effect of monoclonal anti-FSH antibodies against the mouse and corresponding human sequences, which differ by two amino acids (Ji et al. 2018). Both antibodies, Mf4 and Hf2, effectively prevent bone loss post ovarioectomy, with IC50s of 5.4 and 6.1 nM for inhibition of osteoclastogenesis, respectively (Ji et al. 2018).

**FSH effects on body fat and thermogenesis**

Weight gain and changes in body composition are typically seen in women around the menopausal transition. Overall weight gain is prominent in perimenopausal and early postmenopausal women alike and has largely been attributed to aging independent of menstrual status (Sternfeld et al. 1999, Demerath et al. 2011, Trikudanathan et al. 2013, Zsakai et al. 2015). However, changes in body composition, specifically those accruing from visceral adiposity, have been closely linked to the menopausal transition (Gambacciani et al. 1999, Toth et al. 2000, Sowers et al. 2007, Lovejoy et al. 2008, Franklin et al. 2009, Lee et al. 2009, Ho et al. 2010, Janssen et al. 2010). Notably, high FSH levels are associated with increases in waist circumference, waist–hip ratio and visceral fat volume (Gavaler & Rosenblum 2003, Sowers et al. 2007, Seth et al. 2013). Additionally, there seems to be a reduction in lean mass associated with higher FSH levels (Gourlay et al. 2012, Jaff et al. 2015, Liu et al. 2017). In contrast, the 11-year SWAN follow-up and the Pan Asia Menopause study report lower FSH levels in women with higher BMI. This discrepancy may be due to feedback inhibition of FSH secretion by estrogen produced from aromatization in fat tissue (De Pergola et al. 2006, Ausmanas et al. 2007, Tepper et al. 2012). Interestingly, there is no association between FSH and BMI in males (Bienek et al. 2016, Yamacake et al. 2016), despite evidence for the reduction of body fat by FSH inhibition in male mice (Liu et al. 2017) (see below). However, there is limited evidence for a role for FSH in the pathophysiology of metabolic syndrome (Stefanska et al. 2014).

Our overall results attest to a role for FSH in promoting adiposity (Liu et al. 2017). Similar to bone, the adipocyte FSHR, which at least in 3T3.L1 cells is a variant of the ovarian FSHR, couples to Goα – this results in reduced AMP levels and a subsequent decrease in the activation of the mitochondrial protein, uncoupling protein-1 (UCP1) in de-differentiated brown adipocytes (or thermo cells).
This pathway, which opposes $\beta_3$ adrenergic stimulation, has been shown in previous studies to be linked downstream to the activation of cyclic AMP response element-binding protein (CREB) and lipogenesis. Expectedly, in differentiated adipocytes derived from 3T3-L1 cells, FSH increases the expression of genes related to lipid metabolism, namely Lpl, Fas and Pparg (Cui et al. 2012).

Our anti-FSH antibody, which blocks FSH action in the face of unperturbed estrogen levels, not only reduces adiposity in a variety of mouse models, but also induces the transition of white adipocytes to energy-producing beige adipocytes (Liu et al. 2017). These murine models include mature male and female mice fed pairwise or ad libitum on a high-fat diet or on normal chow, sham-operated and ovarioctomized mice, 8-month-old mice, and Fshr$^{−/−}$ mice (Liu et al. 2017). The data have been replicated and reproduced at multiple laboratories using multiple modalities, namely quantitative nuclear magnetic resonance (qNMR), dual-energy X-ray absorptiometry (DXA), $\mu$-CT, and manual weighing of tissues (Liu et al. 2017, Rosen & Zaidi 2017). Equally impressive declines were noted in subcutaneous, visceral, perigonadal, inguinal and bone marrow fat compartments (Liu et al. 2017). The antibody reduced body fat to a level similar to that in haploinsufficient Fshr$^{−/−}$ mice, indicating a dominant action of FSH signaling. Importantly, however, the antibody did not further reduce body fat in these mice, establishing in vivo specificity (Liu et al. 2017).

In addition to inducing leanness, the anti-FSH antibody also induced the production of thermogenic adipose tissue. We noted abundant beige cells in UCP1-stained sections of white adipose tissue. Beiging was contemporaneously documented by implanting Thermo cells into athymic nude mice, as well as through the use of the transgenic ThermoMouse, in which a luciferase (Luc2) gene construct is inserted into the Ucp1 locus to report UCP1 activation. Upon blocking FSH, we found increased LUC2 radiance initially in the brown fat-rich interscapular area, which was followed at around 8 weeks by increased radiance in the inguinal fat, primarily containing white adipose tissue. Quantitative PCR also showed increased expression of brown fat genes in white adipose tissue, namely Ucp1, Cox7, Cidea and Cox8a. Finally, the induced beiging was confirmed by documenting an increase in mitochondrial density in the PhAM mouse, as well as through indirect calorimetry using metabolic cages, where increases in energy expenditure and oxygen consumption were noted (Liu et al. 2017).

**FSH effects on cholesterol metabolism**

There is an increased prevalence of dyslipidemia and cholesterol accumulation around the menopausal transition, which has traditionally been linked to estrogen deficiency (Rossouw et al. 2002). However, there has been recent evidence that FSH might play a role in increasing hepatic cholesterol production, independent of serum estrogen. A recent study of 278 pre- and perimenopausal women found that serum FSH, total cholesterol (TC) and LDL cholesterol (LDL-C) levels were higher in the perimenopausal group compared with pre-menopausal women, despite similar serum estrogen levels (Guo et al. 2019). Serum FSH levels displayed a positive correlation with TC and LDL-C after adjustment for estrogen. Similarly, another study of 588 postmenopausal women noted that subjects with higher serum FSH levels had higher levels of both TC and LDL-C (Serviente et al. 2019).

In a cohort of 400 postmenopausal Chinese women with a similar relationship between serum FSH, TC and LDL-C, it was noted that significant improvement of lipid levels after hormone-replacement therapy was seen only in women who had $\geq$30% reduction in serum FSH levels (Song et al. 2016).

To further substantiate a role for FSH in cholesterol metabolism, Guo et al. used ovarioctomized mice in which estrogen was clamped by exogenous administration. These mice, when injected with recombinant FSH, showed higher levels of serum TC and LDL-C, and elevated hepatic cholesterol biosynthesis (Guo et al. 2019). Furthermore, in contrast to our results where we did not find decrements in serum cholesterol after 8 weeks of anti-FSH antibody treatment (Liu et al. 2017), the authors provide compelling evidence that blocking FSH action either through an anti-FSH$\beta$ antibody or in Fshr$^{−/−}$ mice significantly reduced serum and hepatic cholesterol content, without significantly altering estrogen levels (Guo et al. 2019). The presence of the FSHR in the liver was also established in both human and mouse liver samples using RT-PCR, in situ hybridization and immunofluorescent labeling (Guo et al. 2019). Finally, FSH was shown to upregulate liver HMG-CoA reductase, a rate-limiting enzyme for cholesterol biosynthesis; this effect appears to be regulated through the activation of the transcription factor sterol regulatory element-binding protein 2 (SREBP-2) (Pertusa et al. 2007, Guo et al. 2019). Another possible mechanism of elevated circulating LDL-C is the FSH-mediated reduction in hepatic LDL receptors which results in decreased endocytosis of LDL-C. This was shown both by reduced hepatic LDLR expression in ovarioctomized mice, as well
as FSH-mediated LDLR inhibition in HepG2 cells (Song et al. 2016). Given the small number of studies on the topic, there is room for further exploration of the role of FSH on lipid and cholesterol metabolism and the underlying mechanisms.

Effects on cardiovascular risk

Although several studies have reported an association between serum FSH levels and markers of cardiovascular risk, it remains a controversial subject with lack of consistent findings. The Assessment of the Transition of Hormonal Evaluation and Noninvasive Imaging of Atherosclerosis study used contrast-enhanced CT angiography and carotid ultrasound to find that subclinical atherosclerosis is prevalent in perimenopausal women, with the prevalence of any coronary plaque being as high as 35.5% (Munir et al. 2012). Of note was that the number of aortic plaques was associated directly with serum FSH levels, but was unrelated to serum estrogen (Munir et al. 2012).

Similarly, a study from Brazil noted a significant positive correlation between serum FSH and carotid intima-media thickness, a surrogate for atherosclerosis (Celestino Catão Da Silva et al. 2013). Furthermore, data from a SWAN cohort showed lower serum FSH levels to be associated with a lower carotid intima-media thickness compared to the mid and high FSH groups, although the latter had a superior cardiovascular disease risk profile (El Khoudary et al. 2016). To the contrary, the SPECT-China study, a large, multi-center study on 2658 postmenopausal women, showed a negative association between serum FSH levels and atherosclerotic cardiovascular risk (Wang et al. 2017).

FSH and the biology of aging

Aside from what is now emerging as a critical function for high plasma FSH in causing physiologic perturbations of menopause, there has also been recent speculation for its role in the aging process per se in both sexes (Bartke 2017). Even in men, serum FSH levels rise by 3% per annum (Feldman et al. 2002). In murine models, enhancements in longevity are associated with reduced FSH levels (Bartke 2017). Namely, Ames and Laron dwarf mice, which are deficient in the pituitary transcription factor PROP1 and growth hormone receptor, respectively, display reduced serum FSH, in addition to other pituitary hormones. These mice display increases in brown adipose tissue, similar to what we have reported using our anti-FSH antibody (Bartke et al. 2013, Bartke 2017, Liu et al. 2017). In addition, there is an impressive increase in lifespan and reduced biological aging in these mice. However, further studies are needed to decipher the precise mechanisum(s) underscoring increased longevity. In addition to possible effects on lifespan per se, one might speculate that the relationship between FSH and obesity may confer a survival benefit when FSH is low, particularly as adiposity can independently affect metabolic and cardiovascular outcomes, thus decreasing longevity.

Conclusion

Extensively validated sets of data provide compelling evidence that FSH inhibition reduces body fat and serum cholesterol, induces beiging and thermogenesis, and increases bone mass. Most of these studies have been carried out in animal models, given the ability to study the effects of FSH, somewhat independent of estrogen. This prompts the question whether a single FSH-blocking agent can have the therapeutic novelty of simultaneously treating and/or preventing osteoporosis, obesity and dyslipidemia, diseases that affect millions of women and men worldwide. Highly targeted monoclonal anti-FSH antibodies are thus being developed currently as first-in-class agents for human use. Further studies in humans examining the effects of varying levels of FSH against the above-mentioned parameters would help delineate its exact role, and the potential use of these FSH-blocking antibodies in clinical practice.

Declaration of interest

M Z is a named inventor on a patent related to FSH and bone, owned by Icahn School of Medicine at Mount Sinai. M Z will receive royalties and/or licensing fees per Mount Sinai policies, in case the patent is commercialized. M Z also consults for Merck, Roche, and a number of financial consulting platforms. The other authors have nothing to disclose.

Funding

M Z is grateful to the National Institutes of Health for grant support, namely R01 AG40132, R01 AR67066, R01 DK113627, and U19 AG60917.

References


Iqbal J, Sun L, Kumar TR, Blair HC & Zaidi M 2006 Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. *PNAS* 103 14925–14930. (https://doi.org/10.1073/pnas.0606805103)

Jafft NG, Norris SA, Snyman T, Toman M & Crowther NJ 2015 Body composition in the Study of Women Entering and in Endocrine Transition (SWEET): a prospective of African women who have a high prevalence of obesity and HIV infection. Metabolism: Clinical and Experimental 64 1031–1041. (https://doi.org/10.1016/j.metabol.2015.05.009)


Received in final form 18 August 2019
Accepted 27 August 2019
Accepted Preprint published online 27 August 2019